New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 13, 2012
15:32 EDTEW, MDTMedtronic says appeals court ruling has no impact on CoreValve trials
Medtronic (MDT) confirmed that the Federal Circuit Court of Appeals affirmed the April 2010 jury verdict from the Federal District Court of Delaware that the CoreValve System infringed a single Andersen patent held by Edwards Lifesciences (EW). The Court of Appeals also remanded the case back to the District Court to consider a potential injunction. Medtronic said, "While Medtronic respects the court's ruling, we respectfully disagree with this conclusion and we are evaluating next steps...While Edwards has applied for a patent extension, there is no assurance an extension will be issued or what the impact or duration of that extension would be. These applications involve a review by two government agencies, and the process often can take between 2 and 5 years." Medtronic said the legal actions have no impact on the Medtronic CoreValve U.S. Pivotal Trial, the Medtronic CoreValve SURTAVI Trial, or any other clinical studies evaluating the CoreValve System. Due to its global manufacturing capabilities, Medtronic does not anticipate any interruption to the global supply of the Medtronic CoreValve System, the company added.
News For MDT;EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
19:16 EDTEWOn The Fly: After Hours Movers
Subscribe for More Information
16:19 EDTEWEdwards Lifesciences sees Q2 EPS $1.00-$1.10, consensus $1.05
Subscribe for More Information
16:18 EDTEWEdwards Lifesciences narrows FY15 EPS view to $4.10-$4.30, consensus $4.21
Subscribe for More Information
16:17 EDTEWEdwards Lifesciences reports Q1 EPS $1.12, consensus $1.04
Subscribe for More Information
15:00 EDTEWNotable companies reporting after market close
Subscribe for More Information
April 21, 2015
11:02 EDTMDTMedtronic begins enrollment in feasibility study of Valiant Mona LSA system
Medtronic announced the start of a new feasibility study to evaluate the safety and effectiveness of the Valiant Mona LSA branch thoracic stent graft system, an investigational medical device designed to enable a completely endovascular solution for aortic aneurysms encroaching on the left subclavian artery. Cleveland Clinic cardiothoracic surgeon Dr. Eric Roselli successfully completed the first implant in the study on Thursday. He serves as the study's national primary investigator and receives consulting fees and honoraria for teaching from Medtronic. The study aims to enroll 24 subjects at up to seven sites in the United States. The purpose of the study is to characterize the safety and effectiveness of the investigational device acutely and at 30 days.
April 17, 2015
07:10 EDTMDTMedtronic's Solitaire improved neurological outcomes in stroke patients in trial
Subscribe for More Information
April 14, 2015
11:04 EDTMDTMedtronic to develop stent graft system under patent agreement with Sanford
Subscribe for More Information
09:16 EDTMDTMedtronic announces CE Mark for Micra TPS
Subscribe for More Information
April 13, 2015
17:13 EDTMDTIBM Medtronic to partner to improve diabetes care
IBM (IBM) and Medtronic (MDT) announced that they will work together to combine powerful analytics and cognitive computing with diabetes medical devices and health data to develop a new generation of personalized diabetes management solutions. People using Medtronic diabetes solutions could benefit from new solutions developed in collaboration with IBM's newly-formed Watson Health unit.
17:10 EDTMDTIBM establishes a Watson Health Cloud
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use